Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		63 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (37,814)	$ (40,665)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	146	128
Stock-based compensation	7,048	5,775
Issuance of PIK interest debt	877	848
Accrued interest on revenue interest financing liability	5,154
Amortization of debt discount	496	518
Other	763	591
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(5,143)	(4,384)
Accounts payable and accrued expenses (includes changes in related party amounts of $137 and $2,719, respectively)	(11,303)	(6,075)
Accrued clinical trial expenses		(1,402)
Accrued interest	57	4
Operating right-of-use assets and lease liabilities	50	22
Other long-term assets		(117)
Net cash used in operating activities	(39,669)	(44,757)
Cash flows from investing activities
Cash paid for property, plant and equipment	(214)	(67)
Net cash used in investing activities	(214)	(67)
Cash flows from financing activities
Net cash provided by financing activities	14,072
Net decrease in cash and cash equivalents and restricted cash	(25,811)	(44,824)
Cash and cash equivalents and restricted cash - beginning of period	155,890	183,419
Cash and cash equivalents and restricted cash - end of period	130,079	138,595	$ 130,079
Supplemental disclosure of cash flow information
Interest paid	2,546	1,388
Supplemental disclosure of noncash investing and financing activities
Property and equipment purchases included in accounts payable and accrued expenses		120
Settlement of ESPP liability in common stock	856	515
Settlement of 401(k) liability in common stock	456	$ 254
At-the-Market Offering Program
Cash flows from financing activities
Net proceeds from issuance of common stock	$ 14,072		$ 38,700